Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ia Study of a LentiGen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) Using a Closed Transduction System

NCT07361029 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.

NCT NCT07361029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07361029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ia Study of a LentiGen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) Using a Closed Transduction System
Lead sponsor
King Faisal Specialist Hospital & Research Center
Phase
Phase 1
Overall status
Recruiting
Start date
July 29, 2025
Completion date
July 31, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed refractory acute lymphoblastic leukemia